Article
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.
Blood - 8 Aug 2013
Linette Gerald P, Stadtmauer Edward A, Maus Marcela V, Rapoport Aaron P, Levine Bruce L, Emery Lyndsey, Litzky Leslie, Bagg Adam, Carreno Beatriz M, Cimino Patrick J, Binder-Scholl Gwendolyn K, Smethurst Dominic P, Gerry Andrew B, Pumphrey Nick J, Bennett Alan D, Brewer Joanna E, Dukes Joseph, Harper Jane, Tayton-Martin Helen K, Jakobsen Bent K, Hassan Namir J, Kalos Michael, June Carl H
Abstract excerpt
An obstacle to cancer immunotherapy has been that the affinity of T-cell receptors (TCRs) for antigens expressed in tumors is generally low. We initiated clinical testing of engineered T cells expressing an affinity-enhanced TCR against HLA-A*01-restricted MAGE-A3. Open-label protocols to test th...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.